In the latest episode of Blood Cancer Talks, Alexander Perl, MD, of the University of Pennsylvania, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; to discuss the management of newly diagnosed and relapsed FLT3-positive acute myeloid leukemia (AML).
Dr. Perl and the hosts also discuss the QuANTUM-First trial, which studied quizartinib plus chemotherapy in newly diagnosed patients with FLT3 internal-tandem-duplication-positive AML; the benefit of high-dose daunorubicin in AML induction across cytogenetic and molecular groups; sorafenib maintenance in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem-cell transplantation; and more.
This podcast originally appeared on Blood Cancer Talks.